Cybin Inc. Common Shares CYBN 深 滬
等待開盤 10-10 09:30:00 美东时间
6.27
+0.010
+0.16%
華盛通- 最 高6.35
- 今 開6.26
- 成交量 34.87万股
- 最 低 6.20
- 昨 收 6.26
- 總市值 1.58亿
- 52周最高 13.88
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.81
- 委 比 84.76%
- 總股本 2518.82万
- 歷史最高 122.36
- 量 比 0.39
- 振 幅 2.40%
- 歷史最低 4.81
- 每 手 1
- 風險率 3.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
https://www.marijuanamoment.net/new-york-lawmakers-hold-hearing-psilocybins-medical-benefits-amid-broader-debate-over-psychedelics-reform/
10-02 23:03
Cybin Advances Clinical Programs in Psychedelic Therapeutics
An update from Cybin ( ($TSE:CYBN) ) is now available. Cybin has announced sign...
09-24 05:47
'Massachusetts Lawmakers Approve Bill To Create Psychedelic Therapy Pilot Program' - Marijuana Moment
https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/
09-13 00:30
Cybin to Engage in TD Cowen’s Neuropsychiatry Summit
Cybin ( ($TSE:CYBN) ) has provided an update. Cybin announced its participation...
09-11 20:10
Cybin CEO steps down; co-founder named interim CEO
Doug Drysdale has stepped down as chief executive officer of Cybin (NYSE:CYBN), effective September 2, 2025. Co-Founder and president Eric So has been appointed interim CEO. The board has formed a com...
09-02 19:46
Cybin Names Co-Founder Eric So As Interim CEO As Doug Drysdale Steps Down
Cybin Inc. (NYSE:CYBN) (Cboe Canada:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
09-02 19:34
'U.S. Senate Committee To Hold Hearing On Benefits Of Psychedelics For Military Veterans'- Marijuana Moment
https://www.marijuanamoment.net/u-s-senate-committee-to-hold-hearing-on-benefits-of-psychedelics-for-military-veterans/
08-22 02:35
Cybin reports Q1 results
Cybin press release (NYSE:CYBN): Q1 cash totaled $118.7 million as of June 30, 2025. Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same...
08-14 15:30
Cybin's Clinical Trial Application Approved By Irish Medicines Board To Initiate EMBRACE Study In Ireland, Poland, And Greece
- EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe, the United Kingdom, and Australia -- European CTA
08-07 19:42
